Boston, Mass. – An important discovery from the NCI-MATCH precision medicine initiative is being published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. Trastuzumab-pertuzumab, a drug combination approved by the US Food and Drug Administration (FDA) to treat patients with human epidermal growth factor...
treatment News
BOSTON, Mass. – The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer continues to be regulated by...
FOSTER CITY, Calif. — Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary...
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for their investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were published in The New England Journal of Medicine and presented during an oral presentation at the annual American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) meeting. These latest...
ORLANDO, Fla. — Injecting neuroblastoma tumors with Zika virus shrank or eliminated those tumors in studies with mice, suggesting that the virus could someday serve as an effective cancer therapy, according to a study led by Nemours Children’s Health researchers and published today in Cancer Research Communications, a journal of...
Jacksonville, Florida – Researchers from Nemours Children’s Health will present several studies at the American Society of Hematology (ASH) conference, Dec. 9-12 in San Diego. Nemours Children’s researchers will focus primarily on sickle cell disease (SCD), a group of inherited red blood disorders marked by defective hemoglobin that causes pain...
Bottom Line: Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery—including those who would not have been eligible for surgery by conventional criteria—had similar outcomes to patients who received surgery upfront, according to results from a retrospective study. Journal in Which the Study was Published: Cancer...
FORT MYERS, Fla. — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual...
ROCKVILLE, Md. – NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 portion of a study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in patients with newly diagnosed, non-severe lymphopenic high grade glioma (HGG), following standard...
ROCKVILLE, Md. — NeoImmuneTech, Inc. (NIT), a global leader in T-cell-based immunotherapy, today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa). The poster was presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The study explored...